Form D · Other Health Care
Cyprium Therapeutics, Inc.
New York, NY · CIK 0001890689
Offering snapshot reported Oct 27, 2021 · SEC filing
- Reported sold
- $7M Offering amount: $7M
- Investors reported
- 75 Form D · investor count
- Minimum accepted
- $25K Reported outside-investor minimum
- First sale
- Jul 27, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Oct 27, 2021 | Initial | $7,000,000 | No comparison | 75 | SEC filing |
Offering details
- Securities
- Equity
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $870K
- Finders' fees
- $0
- Form D file number
- 021-418723
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| National Securities Corporation | 7569 |
Source: Form D, filed Oct 27, 2021. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Lindsay A. Rosenwald | Director |
| Lung Yam | Executive |
Issuer details
Industry: Other Health Care (See others in industry)
Address:
2 Gansevoort Street, 9 Th Floor
New York, NY, 10014
New York, NY, 10014